Novo Nordisk targets mid-2027 India launch for oral semaglutide
CHMP also backed a revised type-2 diabetes indication for Kyinsu, while buybacks since February reached DKK 10.88 billion.
TR
By Tom Reyes · Markets Editor
Oct 21 05:50 ETSource: AD HOC NEWS
The wire
- 01India head Vikrant Shrotriya said on October 15 that oral semaglutide could launch in India by mid-2027 subject to clearance, with applications for a higher-dose semaglutide and oral semaglutide in obesity under review.
- 02The EMA's CHMP issued a positive opinion on a revised Kyinsu indication for adults with inadequately controlled type-2 diabetes, though the European Commission decision is still pending.
- 03A post hoc REDEFINE 1 analysis of 2,309 women showed 25.0 percent average weight loss on CagriSema versus 3.0 percent on placebo at 68 weeks; Novo calls the findings hypothesis-generating and CagriSema remains investigational.
From the source
Read at ad-hoc-news.deNovo Nordisk Maps India Rollout for Oral Semaglutide While Buyback Passes DKK 10.8 Billion
Novo Nordisk is sketching out a mid-2027 launch window for oral semaglutide in India, even as the company keeps steadily mopping up its own shares and waits on European regulators to sign off on a label change for Kyinsu.
